Detailed treatment for pneumonia
I'll start by reading the medical library skill, then search for comprehensive pneumonia treatment information.
Reading File
Now I'll run parallel searches across the medical library and PubMed for comprehensive pneumonia treatment information.
Finding Sources
Finding Sources
Searching PubMed
"pneumonia" AND "treatment" AND "guidelines"
Excellent findings. Now let me read the most relevant textbook sections in parallel - the Washington Manual CAP treatment section, Goldman-Cecil HAP/VAP table, and Tintinalli empiric antibiotic section.
Reading File
Reading File
Reading File
Reading Article
PMID: 40679934
I have excellent content now. Let me read more of the Washington Manual CAP treatment table and the HAP/VAP treatment table from Goldman-Cecil for completeness.
Reading File
Reading File
I now have comprehensive data from multiple authoritative textbooks and a 2026 ATS guideline. Let me compile the detailed treatment guide.
Detailed Treatment of Pneumonia
Pneumonia treatment is organized around the site of acquisition (community vs. hospital/ventilator-associated), disease severity, and host immune status. Below is a structured breakdown.
1. Classification & Severity Assessment
Before initiating treatment, classify the patient using validated scoring systems:
- CURB-65 (Confusion, Urea >7 mmol/L, Respiratory rate ≥30, Blood pressure <90 systolic or ≤60 diastolic, Age ≥65): score 0-1 = outpatient, 2 = inpatient, 3-5 = consider ICU
- Pneumonia Severity Index (PSI): Classes I-II = outpatient, III = brief inpatient/observation, IV-V = inpatient/ICU
- All patients should be assessed for oxygenation, comorbidities, and aspiration risk before selecting a regimen.
2. Community-Acquired Pneumonia (CAP)
Diagnostic Workup Before Treatment
- Sputum Gram stain + culture before antibiotics (for all hospitalized patients)
- Blood cultures x2 before antibiotic therapy
- Urinary antigen tests for S. pneumoniae and L. pneumophila in severe disease
- Nasopharyngeal PCR for influenza, SARS-CoV-2, respiratory viruses in selected cases
- Chest radiograph: confirms diagnosis (lobar consolidation, interstitial infiltrates, or cavitation)
- Bronchoscopy for immunocompromised patients or treatment failure
Key principle: Antibiotics should start within 4 hours of diagnosis - delays increase mortality. - The Washington Manual of Medical Therapeutics
2a. Outpatient CAP Treatment
| Patient Type | Regimen |
|---|---|
| No comorbidities, no MRSA/Pseudomonas risk | Amoxicillin 1000 mg PO q8h x5d, OR Doxycycline 100 mg PO q12h x5d, OR Azithromycin 500 mg day 1, then 250 mg days 2-5 |
| With comorbidities (COPD, DM, renal/cardiac/liver disease, alcoholism, malignancy, asplenia) | Amoxicillin-clavulanate 875/125 mg PO q12h OR Cefpodoxime 200 mg PO q12h OR Cefuroxime 500 mg PO q12h PLUS Doxycycline or Azithromycin |
| Comorbidities - monotherapy alternative | Respiratory fluoroquinolone: Levofloxacin 750 mg PO daily OR Moxifloxacin 400 mg PO daily |
Source: The Washington Manual of Medical Therapeutics, Table 14-9
2b. Inpatient CAP (Non-Severe)
- Beta-lactam + Macrolide: Ampicillin-sulbactam 1.5-3 g IV q6h (or Ceftriaxone 1-2 g IV daily, or Cefotaxime 1-2 g IV q8h, or Ceftaroline 600 mg IV q12h) PLUS Azithromycin
- OR Monotherapy: Respiratory fluoroquinolone (levofloxacin or moxifloxacin)
2c. Inpatient CAP (Severe/ICU)
- Beta-lactam PLUS macrolide (first-line combination)
- OR Beta-lactam PLUS fluoroquinolone
If prior respiratory isolation of MRSA: Add Vancomycin 15 mg/kg IV q12h (adjust for renal function and levels) OR Linezolid 600 mg IV/PO q12h
If prior respiratory isolation or high risk for P. aeruginosa: Add Piperacillin-tazobactam 4.5 g IV q6h, or Cefepime 2 g IV q8h, or Ceftazidime 2 g IV q8h, or Imipenem 500 mg IV q6h, or Meropenem 1 g IV q8h, or Aztreonam 2 g IV q8h
Note: Community-acquired MRSA is an important cause of severe, necrotizing pneumonia - always consider when appropriate. - Washington Manual
3. Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP)
Common Pathogens
- S. aureus (MRSA 15-20%), Klebsiella spp. (10%), Enterobacter spp. (5-10%), E. coli (5-10%), H. influenzae (5%), Acinetobacter (3%), Pseudomonas aeruginosa
- 20-25% of HAP may be caused by respiratory viruses alone (rhinovirus, influenza, parainfluenza, metapneumovirus)
General Principles
- Antibiotics can be withheld in clinically stable patients until diagnosis confirmed
- Immediate treatment is mandatory in rapidly deteriorating or hypotensive patients
- Tailor regimens to the patient's individual risk factors and local antimicrobial resistance profiles
Empiric HAP/VAP Treatment
Group A - Early onset HAP/VAP, no MDR risk factors:
- Monotherapy with agents targeting susceptible gram-negative rods (e.g., ceftriaxone, levofloxacin, moxifloxacin, ampicillin-sulbactam, or ertapenem)
Group B - MDR risk factors present (prior IV antibiotics in 90 days, ICU admission, prior MDR isolation):
- MRSA coverage: Linezolid or Vancomycin
- PLUS anti-Pseudomonal coverage (one or two agents from):
- Beta-lactams: Cefepime, Ceftazidime, Piperacillin-tazobactam, Imipenem, Meropenem
- Newer beta-lactam/beta-lactamase inhibitors: Imipenem-relebactam, Ceftolozane-tazobactam, Ceftazidime-avibactam
- Fluoroquinolones: Ciprofloxacin, Levofloxacin
- Others: Aztreonam, Colistin, Cefiderocol
De-escalation: If nasal PCR for MRSA is negative and local MRSA prevalence is <20%, MRSA coverage can be withheld. Narrow coverage once culture and sensitivity results are available. - Goldman-Cecil Medicine
4. Aspiration Pneumonia
- Often polymicrobial; oral anaerobes are a major contributor
- Antibiotics of choice: Amoxicillin-clavulanate, Clindamycin (anaerobic coverage), or Piperacillin-tazobactam
- Aspiration pneumonitis (chemical, non-infectious) does NOT require antibiotics - supportive care only
- Manage underlying risk factors (dysphagia, altered consciousness, GERD)
5. Pneumocystis Pneumonia (PCP) - Immunocompromised Hosts
- Agent: Pneumocystis jirovecii
- Drug of choice: Trimethoprim-sulfamethoxazole (TMP-SMX)
- Mild-moderate: TMP-SMX 15-20 mg/kg/day (TMP component) PO divided q6-8h x21 days
- Severe (PaO2 <70 mmHg or A-a gradient >35): Add adjunctive corticosteroids - Prednisone 40 mg PO BID days 1-5, then 40 mg daily days 6-10, then 20 mg daily days 11-21
- Alternatives: Pentamidine, Clindamycin + primaquine, Atovaquone (mild-moderate)
- Goldman-Cecil Medicine, Table 315
6. Immunocompromised Host Pneumonia
When no pathogen is identified, the radiographic pattern guides empiric therapy:
| Radiographic Pattern | Likely Pathogen | Empiric Therapy |
|---|---|---|
| Lobar consolidation | Bacterial (sometimes postobstructive) | Standard antibacterials |
| Interstitial pattern | Pneumocystis, viral, atypical bacteria | Broad-spectrum antibacterials + consider TMP-SMX for PCP |
| Nodular/cavitary | Bacteria, fungi, Nocardia | Broad-spectrum antibacterials + antifungal; consider Nocardia coverage |
- For serious fungal pathogens, consider antifungal agents targeting Cryptococcus, Aspergillus, or Mucorales species
- Always try to identify the specific pathogen via bronchoscopy/BAL, blood cultures, or tissue biopsy; expectorated sputum is unreliable
- Whenever possible, reduce immunosuppressive dosing to boost host immunity - Goldman-Cecil Medicine
7. Pediatric Pneumonia
Supportive Care (All Ages)
- Supplemental O2 to maintain SpO2 >90-92%
- Antipyretics (paracetamol/ibuprofen)
- Adequate hydration (oral, NG, or IV)
- Bronchodilators only if wheezing with known asthma
- Avoid cough suppressants in children (not effective, codeine discouraged due to respiratory depression risk)
- Honey is an evidence-based and safe cough remedy in children >1 year
Antibiotic Choice by Age/Pathogen
- Viral pneumonia (RSV, influenza, most cases <5 years): Supportive care ONLY - no antibiotics
- Bacterial (presumed): Amoxicillin is first-line for most outpatient bacterial pneumonia
- Life-threatening pneumonia complicating influenza: Vancomycin + an anti-Staphylococcal agent (covers CA-MRSA); de-escalate once cultures available
- Well-appearing febrile infants 28-90 days with confirmed RSV/bronchiolitis: low risk for bacterial co-infection - empiric antibiotics not required - Tintinalli's Emergency Medicine
8. Supportive & Adjunctive Therapy
| Intervention | Details |
|---|---|
| Oxygen therapy | Target SpO2 ≥94% (88-92% in COPD); high-flow nasal oxygen or NIV/CPAP for moderate-severe hypoxemia |
| Corticosteroids | 2026 ATS CAP Guideline recommends systemic corticosteroids for select severe CAP patients; established benefit in severe PCP; IV methylprednisolone or oral prednisone |
| IV fluids | Correct dehydration; monitor for fluid overload especially in elderly |
| Ventilatory support | NIV (BiPAP) for hypercapnic respiratory failure; mechanical ventilation for respiratory failure unresponsive to NIV |
| Physiotherapy | Chest physiotherapy and incentive spirometry to aid mucus clearance |
| Vaccination (prevention) | Pneumococcal vaccine (PCV13 + PPSV23) for age ≥65 and high-risk groups; influenza vaccine annually; COVID-19 vaccine |
9. Treatment Duration
- Outpatient CAP: Minimum 5 days; reassess at 5 days - continue only if not clinically stable
- Inpatient non-severe CAP: 5-7 days when response is good
- Severe or complicated CAP (including Legionella, Pseudomonas, MRSA): 7-14 days
- HAP/VAP: Studies support 8 days for most cases (equivalent outcomes to 15 days with less resistance risk)
- PCP: 21 days total
10. Treatment Failure / Non-Responding Pneumonia
Defined as failure to improve within 48-72 hours of appropriate therapy. Consider:
- Wrong pathogen - atypical, viral, fungal, TB, resistant organism
- Wrong antibiotic - inadequate coverage or dosing
- Complication - parapneumonic effusion, empyema, lung abscess, septic emboli
- Non-infectious mimics - pulmonary edema, PE, cryptogenic organizing pneumonia, vasculitis, drug reaction
- Immunosuppression - re-evaluate host immune status
Bronchoscopy with BAL, CT chest, and repeat cultures are warranted. Broaden coverage empirically while awaiting results. - Murray & Nadel's Textbook of Respiratory Medicine
Recent Guideline Update (2026)
The 2026 ATS Clinical Practice Guideline on CAP (PMID: 40679934) updated evidence-based recommendations on:
- Use of lung ultrasound for diagnosis (promising accuracy)
- Empiric antibacterial therapy when a respiratory virus test is positive (more nuanced approach)
- Antibiotic duration (shorter courses are supported by evidence)
- Role of systemic corticosteroids in select severe CAP patients
Sources: The Washington Manual of Medical Therapeutics (Table 14-9) | Goldman-Cecil Medicine | Tintinalli's Emergency Medicine | Murray & Nadel's Textbook of Respiratory Medicine | Fishman's Pulmonary Diseases and Disorders | ATS Practice Guideline 2026 (PMID: 40679934)
This is a shared conversation. Sign in to Orris to start your own chat.